NFKB1 and ovarian cancer: Our results showed that naringin and NCU-01, combined with DDP, could regulate the TLR4/NF-κB/p38MAPK signaling pathway, repair the damage causing increase intestinal permeability and regulate the composition of intestinal probiotic, which effectively reversed the resistance of ovarian cancer to platinum-based chemotherapeutic agents (Figure 7), and provided a possible drug for the clinical treatment of OC and the reduction of the associated gastrointestinal side effects.